Philip Morris
Statement of Ronald E. Cape, Ph.D President, Cetus Corporation, Berkeley, California Before A Special Joint Congressional Hearing in Conjunction with Oversight Hearings on Science and Technology Policy the Senate Subcommittee on Science, Technology and Space of the Commerce, Science and Transportation Committee Presiding, Senator Adlai Stevenson, III Washington, Dc
Fields
- Author
- Cape, R.E.
- Type
- SPCH, SPEECH/PRESENTATION
- Area
- WAKEHAM,HELMUT/KAROL SHARPE'S OFFICE
- Litigation
- Stmn/Produced
- Site
- R37
- Master ID
- 1000229536/9811
- 1000229537-9544
- 1000229545-9550 Brief Synopsis
- 1000229551-9552 Introduction
- 1000229553-9555 Brief History of Cetus Financing
- 1000229556-9557
- 1000229558-9560 Special Note to Investors
- 1000229561-9563 Special Note Regarding Founder's Stock
- 1000229567-9569 Board of Directors
- 1000229575-9580 Achievements of Cetus People
- 1000229581-9599 Present Cetus Activities
- 1000229600-9616 Research Plan
- 1000229617-9619 Patents
- 1000229621-9656 Debenture Purchase Agreement
- 1000229657-9661 the Cetus Story
- 1000229663-9667 Cloning Business: It's Growing Fast It's Growing Fast
- 1000229668 World Roundup
- 1000229669-9670 Latin Drive: Brazil Spends Millions to Put Alcohol in Cars and Save Oil
- 1000229671 Can US Reduce Imports with Gasoline? Some Say Yes, But Officials Are Dubious
- 1000229672-9673 Bacterial Insulin Production Hears Reality
- 1000229674 Business World
- 1000229675-9677 Who Should Play God?
- 1000229678 Schering Plough New York Analysts' Meeting December 7, 1977
- 1000229679 Indiana Standard Labels Purchase Offer Part of Move to Wider Technology Base
- 1000229680 Big Deal for Berkley Bugs
- 1000229681 Oil-Less World May Run on Bugs
- 1000229682-9685 Tinkering with Life
- 1000229686-9687 Set for Biology's New Revolution
- 1000229688 Little Black Box of Cetus
- 1000229689-9695 Industry Is Finding More Jobs for Microbes
- 1000229696-9701 Dup of Id 1000229657-9661
- 1000229702-9710 Recombinant Molecular Research at Cetus Corporation
- 1000229711-9715 New Cetus Antibiotic
- 1000229716-9720 Letter to the Shareholders
- 1000229721-9726 Letter to Shareholders
- 1000229727-9728 Letters to the Shareholders
- 1000229729-9730
- 1000229731-9734 Letter to the Shareholders
- 1000229735-9736 Letter to Shareholders
- 1000229737-9749 the Manipulation of Genes
- 1000229750-9770 Microbial Genetics and the Future of the Pharmaceutical Industry
- 1000229771-9774 Recombinant Dna: Fact and Fiction
- 1000229775-9778 Testomony of Ronald E Cape, Phd President, Cetus Corporation, Berkeley, California Before the House Subcommittee on Science, Research and Technology
- 1000229779-9797 Biosystems Poised for Growth
- 1000229798-9805 Testimony of Ronald E. Cape, Ph.D President, Cetus Corporation, Berkley, California Before the Senate Subcommittee on Science, Technology and Space
- 1000229808-9811 Statement of Ronald E. Cape, Ph.D. President, Cetus Corporation, Berkeley, California at the Annual Meeting of the American Association for the Advancement of Science Session on Recombinant Dna Public Health and Biomedical Research Policy Washington, D.C.
Related Documents:
Document Images
atement of Ronald E 'Cape PhD
.,..
President, Cetus Corporation, Berkeley, California ,
Before a Special Joint Congressional Hearing
In Conjunction with Oversight Hearings on Science and Technology Policy`
4~eR_
,,e,.,,,-4,r,The Senate Subcommittee on Science, Technology and Space -~ -
~~t ,, of the Commerce, . Science and Transportation Committee -"W~
~`-Presiding, Serator Adlai Stevenson III
.,
i
'~ _Washington, D.C.
a~
. ~
' .Y.:.... ./ . .
-'K:~. t ' . ..
. .. ~ .
February 14, 1978
"i
ti;
J
I
z:
_, `
~
am president of a small new company in a highlyinnovative field
7R .
molecular biology - exemplified most recently by recombinant DNA activity -
whicYi~ has received so much publicity lately.
FZ~''~~'~~}=~+i i?rr
I would offer two observations. ~^'
".:a , 3
~6`,r":L tw
First:.--As Dr fHannay pointed out, there is substantial hesitation on .,
~t
the part of U.S. industry to become involved in innovative fields, and
it's true~inCrecombinant DNA, too. I speak from several years'of exper-
ience in trying'to~sell it. By and large the response has been,-"if the
activity won't pay back the investment in two or three years, sorry, ,;
we're not in'terested.".Mr.-'Chairman, whatever the complex causes, this-:
attitude is a"'siibstantial departure from
the imagination and guts that
the public debate regarding
Second: Many of us ha've participated in
..~ .
regulation of recombinan't-.DNA activities
held by the two subcommittees with'us here
. ... . . . . -_~:. -. :~... ..~ r~
... , .. . . .:....~.. .. _. ..:~... .
I want to say that my company very much wants
f all work in this field, including, of course, work in industry.
But the point I want to make here, this morning, is that, almost without
exception, those people who have been most vocal in opposing recombinant
k ho want it severel restricted - those eo le are almost '
DNA wor , or w y p p
unanimously and outspokenly hostile to the private sector, hostile to: "
and suspicious of industry. Some go so far as to suggest that the'best
way to develop this technology is to keep it out of the hands of industry:
S
SJ
1
4
1
J
i; J,v . . . . .,~..:~p~. ..
.
r
d
_~.~__ .. - . .. .... ... . . . .- .. -
-wi:
,R a?jv+scqp..-,
y E
~
aF
l]
1
R
